Premium
Nature of the proposed anti‐hyperglycemic chromium(III) malate
Author(s) -
Vincent John B.,
Smart Megan,
Tannehill Haley,
Brown Silas
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.638.2
Subject(s) - chromium , electron paramagnetic resonance , chemistry , mass spectrometry , nuclear chemistry , inorganic chemistry , nuclear magnetic resonance , organic chemistry , physics , chromatography
Chromium(III) complexes have been explored as anti‐diabetic agents. Recently several rodent studies of diabetes and related conditions have used “chromium(III) malate” and shown that the compound exhibits anti‐hyperglycemic properties. Unfortunately, chromium(III) malate is poorly characterized; additionally, multiple synthetic procedures have been reported that appear to be inconsistent. Hence, the synthesis and characterization of chromium malate have been examined in detail. Infrared, UV/visible, NMR and EPR spectroscopies; magnetic susceptibility measurements; elemental analysis; and mass spectrometry were used to characterize chromium(III) malate. Mass spectrometric, magnetic susceptibility and EPR studies suggest that chromium(III) malate contains a trinuclear chromium(III) basic carboxylate type core with the formula [Cr 3 (malate) 4 O] − . Support or Funding Information Funding was provided as part of a National Science Foundation Research Experiences for Undergraduates (REU) award (CHE 1358971) to J.B.V. and Stephen A. Woski.